Update on NICE and SMC collaboration on MTA for cystic fibrosis

The appraisal was discussed by the multiple technology appraisal (MTA) committee on 14 December 2023. NICE will liaise with key stakeholders to determine the next steps. This will include exploring potential commercial solutions.

While the MTA is underway the existing arrangements in England and Scotland for access to these medicines will continue. This will be the case for people starting or already taking these treatments. Irrespective of the appraisal outcome there will be continued access after the appraisal ends for patients already receiving any of these medicines.

A further update on next steps and timelines will be provided in the week commencing 22 January 2024.

Further information is available here: https://www.nice.org.uk/guidance/gid-ta11187/documents/supporting-documentation